Brief: Paratek Pharmaceuticals To Acquire Optinose for Up To $330 Million

OptiNose

20/03/2025 01:29

March 19 (Reuters) - Paratek Pharmaceuticals:

PARATEK PHARMACEUTICALS TO ACQUIRE OPTINOSE, CREATING SIGNIFICANT COMMERCIAL EXPANSION OPPORTUNITIES FOR XHANCE® IN CHRONIC RHINOSINUSITIS (CRS)

PARATEK PHARMACEUTICALS - TOTAL TRANSACTION VALUE OF UP TO $330 MILLION

PARATEK PHARMACEUTICALS- POTENTIAL CONSIDERATION OF UP TO $14 PER SHARE, INCLUDING UPFRONT CONSIDERATION OF $9 PER SHARE

Source text: ID:nGNX9VT9jn

Further company coverage: OPTN.O

 ((Reuters.Briefs@thomsonreuters.com;))